Financial Comparison: GeoVax Labs (NASDAQ:GOVX) vs. Silverback Therapeutics (NASDAQ:SBTX)

Silverback Therapeutics (NASDAQ:SBTX) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Earnings & Valuation

This table compares Silverback Therapeutics and GeoVax Labs”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48 million	($2.42)	-4.36
GeoVax Labs	$3.09 million	7.54	-$25.97 million	N/A	N/A

GeoVax Labs has higher revenue and earnings than Silverback Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Silverback Therapeutics and GeoVax Labs, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0	0	0	0	0.00
GeoVax Labs	0	0	5	2	3.29

GeoVax Labs has a consensus target price of $14.20, suggesting a potential upside of 474.90%. Given GeoVax Labs’ stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Silverback Therapeutics.

Risk and Volatility

Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.24, indicating that its stock price is 224% more volatile than the S&P 500.

Institutional and Insider Ownership

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 5.7% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Silverback Therapeutics and GeoVax Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
GeoVax Labs	N/A	-809.87%	-349.34%

Summary

GeoVax Labs beats Silverback Therapeutics on 7 of the 11 factors compared between the two stocks.

About Silverback Therapeutics

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

About GeoVax Labs

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.